Biomaterials for intranasal and inhaled vaccine delivery

Cahn, Devorah; Amosu, Mayowa; Maisel, Katharina; Duncan, Gregg A.

doi:10.1038/s44222-022-00012-6

Cited by 17 publications

(15 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 56 Moreover, it is unclear if vaccinated people have immune protection in the nasal mucosa. 57 Hence, nanoparticle virus traps localized in the nasal cavity could be an effective first line of defense in binding and neutralizing incoming viruses.…”

Section: Discussionmentioning

confidence: 99%

Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection

Yathindranath,

Safa,

Tomczyk

et al. 2024

IJN

View full text Add to dashboard Cite

Purpose The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lingering threat to public health has fueled the search for effective therapeutics to treat SARS-CoV-2. This study aimed to develop lipid nanoparticle (LNP) inhibitors of SARS-CoV-2 entry to reduce viral infection in the nose and upper airway. Methods Two types of LNP formulations were prepared following a microfluidic mixing method. The LNP-Trap consisted of DOPC, DSPC, cholesterol, and DSPE-PEG-COOH modified with various spike protein binding ligands, including ACE2 peptide, recombinant human ACE2 (rhACE2) or monoclonal antibody to spike protein (mAb). The LNP-Trim consisted of ionizing cationic DLin-MC3-DMA, DSPC, cholesterol, and DMG-PEG lipids encapsulating si ACE2 or si TMPRSS2 . Both formulations were assayed for biocompatibility and cell uptake in airway epithelial cells (Calu-3). Functional assessment of activity was performed using SARS-CoV-2 spike protein binding assays (LNP-Trap), host receptor knockdown (LNP-Trim), and SARS-CoV-2 pseudovirus neutralization assay (LNP-Trap and LNP-Trim). Localization and tissue distribution of fluorescently labeled LNP formulations were assessed in mice following intranasal administration. Results Both LNP formulations were biocompatible based on cell impedance and MTT cytotoxicity studies in Calu-3 cells at concentrations as high as 1 mg/mL. LNP-Trap formulations were able to bind spike protein and inhibit pseudovirus infection by 90% in Calu-3 cells. LNP-Trim formulations reduced ACE2 and TMPRSS2 at the mRNA (70% reduction) and protein level (50% reduction). The suppression of host targets in Calu-3 cells treated with LNP-Trim resulted in over 90% inhibition of pseudovirus infection. In vivo studies demonstrated substantial retention of LNP-Trap and LNP-Trim in the nasal cavity following nasal administration with minimal systemic exposure. Conclusion Both LNP-Trap and LNP-Trim formulations were able to safely and effectively inhibit SARS-CoV-2 pseudoviral infection in airway epithelial cells. These studies provide proof-of-principle for a localized treatment approach for SARS-CoV-2 in the upper airway.

show abstract

Section: Discussionmentioning

confidence: 99%

Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection

Yathindranath,

Safa,

Tomczyk

et al. 2024

IJN

View full text Add to dashboard Cite

show abstract

“… 3 The potential for exploration in this field is immense; not only can varying the delivery route help exploit mucosal immunity for various diseases, but it can also be pertinent, especially in vaccine development targeting respiratory infections like tuberculosis and respiratory syncytial virus. 4 Xing et al also demonstrate a comparative study between intranasal and intramuscular administration of a tuberculosis vaccine, and the intranasally vaccinated group had better survival rates post-challenge. 5 Another significant advantage of exploring intranasal delivery of vaccines is that it is easier to administer for non-medical personnel by being needle-free.…”

Section: Introductionmentioning

confidence: 96%

In vivo biocompatibility of ZIF-8 for slow release via intranasal administration

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Since colloidal systems are so significant for biological activities, scientists have synthesized many colloidal particles for investigating biological activities or treating diseases. Synthetic nanoparticle vaccines, containing nucleic acid or protein, can penetrate the mucus barrier and directly stimulate the antigen-specific T cells through antigen and antibody interaction, triggering the downstream biological response. , Beyond the direct chemical stimulation, in order to have a better manipulation and spatial control over the synthetic colloid system, scientists use a variety of external stimulation, including optical, magnetic, electrical, and acoustic stimulations . Optical stimulation can be utilized via the photoelectrical effect of semiconductor-based biointerfaces, such as silicon nanowires, which utilize light-induced stimulation for nongenetic modulation .…”

Section: Introductionmentioning

confidence: 99%

Perspectives on Multiscale Colloid-Based Materials for Biomedical Applications

Li,

Huberman-Shlaes,

Tian

2023

Langmuir

View full text Add to dashboard Cite

Colloid-based materials with tunable biophysical and chemical properties have demonstrated significant potential in a wide range of biomedical applications. The ability to manipulate these properties across various size scales, encompassing nano-, micro-, and macrodomains, is essential to enhancing current biomedical technologies and facilitating the development of novel applications. Focusing on material design, we explore various synthetic colloid-based materials at the nano- and microscales and investigate their correlation with biological systems. Furthermore, we examine the utilization of the self-assembly of colloids to construct monolithic and macroscopic materials suitable for biointerfaces. By probing the potential of spatial imaging and localized drug delivery, enhanced functionality, and colloidal manipulation, we highlight emerging opportunities that could significantly advance the field of colloid-based materials in biomedical applications.

show abstract

Biomaterials for intranasal and inhaled vaccine delivery

Cited by 17 publications

References 12 publications

Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection

Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection

In vivo biocompatibility of ZIF-8 for slow release via intranasal administration

Perspectives on Multiscale Colloid-Based Materials for Biomedical Applications

Contact Info

Product

Resources

About